التفاصيل البيبلوغرافية
| العنوان: |
Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis. |
| المؤلفون: |
Lan-Lan Xiao, Xiao-Wei Xu, Kai-Zhou Huang, Ya-Lei Zhao, Ling-Jian Zhang, Lan-Juan Li |
| المصدر: |
BioMed Research International; 11/29/2019, p1-8, 8p |
| مصطلحات موضوعية: |
HEPATITIS B treatment, AGE distribution, ARTIFICIAL organs, BILIRUBIN, HEPATITIS B, LIVER, LIVER failure, MEDICAL cooperation, PROBABILITY theory, RESEARCH, SERUM albumin, SURVIVAL analysis (Biometry), MULTIPLE regression analysis, TREATMENT effectiveness, RETROSPECTIVE studies, KAPLAN-Meier estimator, DISEASE complications |
| مصطلحات جغرافية: |
CHINA |
| مستخلص: |
Background. Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ALCF) is a complicated syndrome with extremely high short-term mortality. -e artificial liver support system (ALSS) may improve the liver function for patients with HBV-ACLF, but the data on its short-term outcomes are insufficient in China. Methods. We recruited HBV-ACLF patients in this nationwide, multicenter, retrospective study. Patients with HBV-ACLF were diagnosed by the COSSH-ACLF criteria. Propensity score matching (PSM) analysis was used to generate compared pairs. -e short-term (28/90 days) survival rates between the standard medical therapy (SMT) group and ALSS group were calculated using a Kaplan-Meier graph. Result. In total, 790 patients with HBV-ACLF were included in this retrospective study; 412 patients received SMT only (SMT group), and 378 patients received SMTand ALSS treatment (ALSS group). PSM generated 310 pairs and eliminated the baseline differences between the two groups (p > 0.05 for all baseline variables). -e probabilities of survival on day 28 were 65.2% (205/310) in the ALSS group and 59.0% (185/310) in the SMTgroup; on day 90, they were 51.0% (163/310) and 42.3% (136/310). -e short-term (28/90 days) survival rates of the ALSS group were significantly higher than those of the SMTgroup (p = 0.0452 and p = 0.0187, respectively). Compared to receiving SMTalone, treatment with ALSS was associated with a significant reduction in serum bilirubin levels and the model for end-stage liver disease (MELD) scores at day 7 and day 28. Multivariate logistic regression analysis revealed that older age, high total bilirubin (T-Bil), low albumin, high ALT, high MELD scores, and high COSSH-ACLF grade were independent baseline factors associated with poor prognosis. Conclusions. -is retrospective study found that compared to SMT, the ALSS improved the short-term (28/90 days) survival rates and laboratory parameters in HBV-ACLF patients. -e ALSS had a better therapeutic effect than SMT for patients with HBV-ACLF in China. [ABSTRACT FROM AUTHOR] |
|
Copyright of BioMed Research International is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder